Previous Article | Next Article ![]()
Infection and Immunity, August 2000, p. 4736-4745, Vol. 68, No. 8
Institut de Pharmacologie et de Biologie
Structurale, Centre National de la Recherche Scientifique, UPR
5089, Toulouse, France
Received 18 October 1999/Returned for modification 15 December
1999/Accepted 17 April 2000
Complement receptor type 3 (CR3) was initially described as an
opsonic receptor. Subsequently, CR3-mediated lectin-sugar recognition mechanisms have been shown to play a major role in the nonopsonic phagocytosis of several pathogens, among them Mycobacterium
tuberculosis. Little is known about the binding and signal
transduction mechanisms operating during nonopsonic ingestion through
CR3 of different microorganisms. In the present study, we used CHO
cells stably transfected with CR3 to show that CR3 was able to mediate
internalization of zymosan and pathogenic mycobacteria
(Mycobacterium kansasii and Mycobacterium
avium) but not that of nonpathogenic species (Mycobacterium
smegmatis and Mycobacterium phlei). A combination of
mannan and Phagocytes play a crucial role in
host defense through their ability to recognize, ingest, and
destroy invading microorganisms. Phagocyte-specific membrane
receptors bind to their corresponding ligands on a microbe's surface
and induce the internalization of microorganisms by phagocytosis.
Concomitantly, signal transduction pathways are initiated, which may
lead to activation of the respiratory burst enzyme NADPH oxidase,
fusion of lysosomal granules with phagosomes, and eventually the
killing of microbes.
Some microorganisms are able to survive within phagocytes, depending on
the selective use of particular phagocytic receptors which mediate
phagocytosis without inducing bactericidal functions (1, 23,
57). For example, phagosomes containing Mycobacterium tuberculosis, the etiological agent of tuberculosis, fuse with lysosomes when the bacteria are serum opsonized prior to macrophage infection, thus recruiting opsonic receptors for phagocytosis, but do
not fuse under nonopsonic conditions (1). Similarly, NADPH
oxidase activity is stimulated only when mycobacteria enter human
macrophages under opsonic conditions (2). The choice of host
cell receptor and the mechanisms of binding (opsonic versus nonopsonic)
may thus influence the fate of intracellular pathogens. There is
therefore considerable interest in identifying the receptors responsible for specific recognition of pathogens and the cellular consequences of such recognition. Among phagocytic receptors, complement receptor type 3 (CR3) is of particular interest, since it is
the target of diverse groups of intracellular parasites (6,
16, 22, 35, 38, 47, 61), such as M. tuberculosis (8, 9, 21, 52, 53; L. S. Schlesinger, A. Frist, T. Kaufmann, R. R. Ingalls, R. Li, D. T. Galenbock, and M. A. Arnaout, Keystone Conference,
abstr. 223, 1999).
CR3 (also termed Mac1) is a member of the Distinct functional binding domains have been predicted or identified
in the extracellular portion of the CD11b subunit of CR3 by
immunologic, mutagenic, and biochemical approaches (3, 7, 12, 14,
19, 26, 31, 51, 55, 56, 58, 59, 65). The first binding domain of
the CD11b subunit, called the I or A domain, is essential for iC3b
binding but also supports ICAM-1, fibrinogen, and factor X recognition
(14). However, the binding sites are not identical for all
of these ligands, since ICAM-1 and iC3b interact with overlapping but
distinct sites within the I domain of CD11b (14). The
existence of a second binding domain responsible for nonopsonic binding
to CR3 was demonstrated by using anti-CR3 monoclonal antibodies (MAbs)
or synthetic peptides that blocked the binding of iC3b but not that of
nonopsonic ligands and vice versa (12, 40, 63). This second
domain, which presents lectin activity, has been identified and located
C terminal to the I domain (55). The lectin domain binds to
soluble Zymosan, isolated from Saccharomyces cerevisiae, is mainly
composed of mannan and Media and reagents.
Mannan, Monoclonal anti-CR3 and other antibodies.
A panel of
mouse MAbs that had previously been reported to bind and functionally
block distinct epitopes of CD11b extracellular domains were used: 2LPM
{immunoglobulin G1(
0019-9567/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Nonopsonic Phagocytosis of Zymosan and Mycobacterium
kansasii by CR3 (CD11b/CD18) Involves Distinct Molecular
Determinants and Is or Is Not Coupled with NADPH Oxidase
Activation
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-glucan inhibited the phagocytosis of zymosan but had no
effect on M. kansasii ingestion. Among six monoclonal
antibodies (MAbs) directed against the CD11b subunit of CR3 that
decreased zymosan ingestion, only three inhibited M. kansasii phagocytosis. In particular, MAbs known to block the CR3
lectin site affected only internalization of zymosan. Using U937
macrophages, we observed that zymosan ingestion through CR3 induced
superoxide production measured by cytochrome c reduction
and by translocation of the NADPH oxidase cytosolic component p47phox
to the phagosomal membrane, whereas phagocytosis of viable or
heat-killed M. kansasii did not. Furthermore, lack of
superoxide anion production during phagocytosis of M. kansasii was not due to inhibition of NADPH oxidase per se or
superoxide anion scavenging. Together, our results indicate that (i)
nonopsonic phagocytosis of zymosan and M. kansasii by CR3
implicates different molecular mechanisms involving multiple and
distinct epitopes of CD11b and (ii) CR3 may transduce different cellular responses depending on the sites mediating nonopsonic phagocytosis.
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2 family of integrins
expressed on the plasma membranes of mammalian phagocytes and natural
killer cells (see references 17, 42, and
49 for a review). It is a heterodimeric type I
transmembrane glycoprotein, consisting of a CD11b
chain
noncovalently associated with the CD18
subunit (17, 42,
49). It was first described as an adhesion molecule involved in
phagocyte diapedesis through interaction with ICAM-1 expressed on
endothelial cells or with the extracellular matrix (17) and
as an opsonic receptor that recognizes complement fragment iC3b
deposited on microorganisms (42, 49). More recent data
indicate that CR3 also serves in the nonopsonic recognition of microbes
by interacting directly with a wide spectrum of molecules on their
surfaces (9, 20, 38, 44, 58, 62).
-glucan and mediates phagocytosis of particles containing
-glucan, such as zymosan (10, 40). For this reason, it
has been suggested that CR3 corresponds to the phagocyte
-glucan
receptor (10, 41, 55). More recently, it has been reported
that CR3 has a broader sugar specificity than originally appreciated,
since it also interacted with mannose,
N-acetyl-D-glucosamine (NADG), and glucose
(55). This dual specificity for mannose- and
glucose-containing polysaccharides has suggested that CR3 has either
two lectin sites or a unique site which recognizes different types of
sugars (55, 65).
(1-3)-glucan (15), whereas
mycobacteria present a large variety of complex sugars on their
surfaces (11). Both particles are ingested nonopsonically by
macrophages via CR3 (8, 9, 21, 40, 52, 53;
Schlesinger et al.) and mannose receptor (2, 45, 50).
Phagocytosis of zymosan through its glucan component has been shown to
trigger the production of superoxide anions
(O2
) (2, 10, 24), whereas the
ingestion of mycobacteria did not (2). Because CR3 seems to
possess distinct nonopsonic lectin sites, and because zymosan and
mycobacteria display different sugar compositions, we asked whether the
different behaviors of these two particles could be related to a
specific mode of interaction with CR3. To address this question and to
further characterize the nonopsonic binding site(s) of CR3, we measured
the effects of polysaccharides and blocking antibodies on the
internalization of zymosan and mycobacteria by CR3-transfected
Chinese hamster ovary (CHO) cells. In addition, using differentiated
U937 cells, which express CR3 but not the mannose receptor, we
compared O2
production in response to
nonopsonic phagocytosis of zymosan and mycobacteria.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
-glucan from barley [a
mixture of
(1,4)glucan and
(1,3)glucan], NADG, laminarin
[
(1,3)glucan], glycogen, superoxide dismutase, ferricytochrome
c, and fluorescein isothiocyanate (FITC) were from Sigma
Chemical Co. (St. Louis, Mo.).
-Glucan, purified from M. tuberculosis as previously described (30), was kindly provided by M. Daffé (Toulouse, France). 9-cis
retinoic acid (RA) was from ICN (Orsay, France), and 1,25-dihydroxy
vitamin D3 (VD3) was kindly provided by U. Fischer and P. Weber (Hoffmann-La Roche, Basel, Switzerland). RPMI
1640, alpha-modified Eagle medium (
-MEM), L-glutamine,
and antibiotics were purchased from Gibco (Cergy Pontoise, France).
) [IgG1(
)]; Dako, Glostrup, Denmark},
LM2/1 (IgG1), and OKM1 (IgG2b), kindly provided by M. R. W. Ehlers (Cape Town Medical School, South Africa)
(8), and CBRM 1/20 (IgG1), CBRM 1/23 (IgG2a), and CBRM
1/32 (IgG1), generously provided by T. A. Springer (Harvard
Medical School, Boston, Mass.) (14). The regions of CD11b
reactive with the MAbs are illustrated below (see Fig. 3).
CR3-transfected and WT CHO cells.
CR3-transfected CHO-Mac1
cells, obtained from T. A. Springer, are CHO cells stably
expressing wild-type (WT) human CR3 (14). A subclone of
CHO-Mac1 cells which expresses CD11b/CD18 at a high rate (8)
was used in the present study. WT and CR3-transfected CHO cells were
cultured in
-MEM supplemented with 10% heat-inactivated fetal
bovine serum, L-glutamine, and, for CR3-transfected cells, 0.1 µM methotrexate (8). The cells were subcultured every
3 to 4 days with phosphate-buffered saline (PBS) containing 5 mM EDTA.
U937 cell culture and differentiation. U937, a human monoblast cell line, was cultured in RPMI 1640 supplemented with 10% heat inactivated fetal bovine serum, L-glutamine, and antibiotics in a 5% CO2 humidified atmosphere. Differentiation into macrophages was induced with a combination of RA (0.1 µM) and VD3 (0.1 µM) for 3 days (33). On day 2, fresh medium containing the differentiation agents was added (32). The extent of differentiation was assessed by monitoring growth arrest, adhesion, and morphological changes (May-Grünwald-Giemsa staining) (27), expression of the differentiation marker CD11b was monitored by flow cytometry analysis (see below), and mannose receptor was monitored by Western blotting (2).
NADPH oxidase activity assessment. The capacity to generate superoxide anions was assessed by the superoxide dismutase-inhibitable ferricytochrome c reduction method (29). Translocation of the p47phox cytosolic subunit of NADPH oxidase was analyzed by immunofluorescence microscopy (13). Briefly, 1 h after infection with either zymosan or M. kansasii, both stained by FITC, U937 cells were fixed and permeabilized in methanol. The cells were incubated in PBS supplemented with 3% bovine serum albumin (BSA) for 30 min at room temperature and then incubated with rabbit anti-p47phox antibodies (1:1,000) for 1 h at room temperature, washed in PBS, and revealed by TRITC-conjugated goat anti-rabbit antibodies. Anti-p47phox antibodies were generously provided by W. B. Nauseef (Veterans Administration Medical Center, University of Iowa) (13). The specificity of the staining was assessed by omission of the primary antibody. Slides were viewed using a Zeiss confocal microscope. In each case, at least 20 cells per slide from each of the three experiments performed were viewed.
Analysis of CR3 expression by flow cytometry. CR3-transfected CHO and U937 cells were washed twice with PBS supplemented with 0.5% BSA, pH 7.4 (PBS-BSA), at 4°C, and incubated for 30 min on ice with or without the primary antibody (2LPM, diluted 1/50). The cells were washed three times in PBS-BSA and incubated with FITC-conjugated goat anti-mouse IgG for 30 min at 4°C. After being washed, the cells were fixed with 3.7% paraformaldehyde for 45 min on ice, washed again, and resuspended in PBS. The adherent cells were gently scraped off and resuspended in PBS. The cells were then analyzed on a FACScan (Becton Dickinson, San Jose, Calif.) as previously described (27).
Bacterial culture and FITC staining. M. kansasii (ATCC 124478), M. smegmatis (ATCC 607), and M. phlei (ATCC 11758) were grown at 37°C as surface pellicles in Sauton broth medium; M. avium (IP 140310013) was cultured in suspension in Middlebrook 7H9 medium (Difco, Bonneuil sur Marne, France). Mycobacteria were prepared as previously described (34). For FITC staining, 109 bacteria were added to 1 ml of 0.01% FITC in 0.2 M Na2CO3-NaHCO3 buffer, pH 10.2, for 10 min and washed with PBS, pH 7.4 (34).
Opsonization of zymosan and mycobacteria. Zymosan or mycobacteria were incubated in pooled normal or heat-inactivated human serum for 20 min at 37°C, washed twice in PBS, pH 7.4, and resuspended in PBS containing 1 mM CaCl2 and 0.5 mM MgCl2 (28). The number of particles or bacteria after opsonization was estimated by quantification in a Thoma chamber.
Infection of CHO and U937 cells and phagocytosis assay by
immunofluorescence microscopy.
WT and CR3-transfected CHO cells
(5 × 104/ml) or U937 cells (2 × 105/ml) were seeded on 12-mm-diameter glass coverslips in
24-well plates. The CHO cells were grown overnight at 37°C, and the
U937 cells were differentiated for 3 days on coverslips as described above. To remove all traces of seric proteins, the cells were washed
twice in
-MEM or RPMI medium supplemented with
L-glutamine and were preincubated at 37°C for 30 min. All
further incubations were performed in the absence of serum. Zymosan
particles or FITC-labeled mycobacteria were then added at a
multiplicity of infection of 50:1. When indicated, zymosan and the
mycobacteria were opsonized in human serum or the mycobacteria were
heat killed (30 min at 80°C) prior to infection. The cells and
particles were left in contact overnight for CR3-transfected CHO cells
or for 1 h for U937 cells. The cells were then extensively washed
with
-MEM or RPMI medium and fixed. For zymosan, the cells were
fixed and permeabilized with methanol for 6 min at
20°C, rinsed in
PBS containing 0.1% Tween 20, and unspecifically stained with
FITC-conjugated antibodies (28). After this treatment, the
cells were uniformly fluorescent and extracellular zymosan was readily
distinguished from internalized particles, which appeared as yellowish
grains within a dark phagosome bordered by diffuse green staining. For mycobacteria, the cells were fixed for 45 min at room temperature with
3.7% paraformaldehyde in PBS containing 15 mM sucrose, and aldehyde
groups were neutralized with 50 mM NH4Cl. The cells were washed in PBS, and extracellular mycobacteria were stained with rabbit
anti-mycobacterium antibodies revealed by TRITC-conjugated anti-rabbit
antibodies. Since the cells were not permeabilized, anti-mycobacterium
antibodies did not reach intracellular bacteria, which thus appeared as
green fluorescent particles (bacteria are prestained with FITC prior to
infection experiments). Extracellular mycobacteria were stained with
antibodies and were therefore fluorescent in red and green. For each
set of conditions, duplicate experiments were performed, and at least
100 cells per slide were counted by fluorescence microscopy to
determine the percentage of cells that had ingested at least one
particle or bacterium.
Inhibition of phagocytosis of zymosan and mycobacteria.
To
block the phagocytosis of zymosan particles or mycobacteria, the
transfected CR3-CHO or U937 cells were preincubated for 30 min at
37°C with the indicated MAbs or polysaccharides diluted in serum-free
-MEM or RPMI 1640 prior to the addition of zymosan or M. kansasii. We verified that the preincubation time and temperature were optimal to obtain an efficient blockade of CR3. Different dilutions of MAbs and concentrations of polysaccharides were tested for
inhibition of zymosan or M. kansasii internalization by
CR3-CHO cells, and the most efficient conditions were as follows: 100 µg of laminarine/ml, 1 mg of
-glucan/ml (from barley), 500 µg of
-glucan/ml, 1 mg of NADG/ml, 1 mg of glycogen/ml, 1 mg of mannan/ml,
1/50 dilution (2 µg/ml) of 2LPM, 1/5 dilution of LM2/1 hybridoma
supernatant, 1/100 dilution of CBRM antibodies, 1/100 dilution of OKM1,
and 5 µg of IgG1 and IgG2 controls/ml. The effects of MAbs and
polysaccharides on cell viability and morphology were assessed by
trypan blue exclusion and light microscopy.
Statistics. Data are presented as the mean ± standard error of the mean (SEM) of the indicated number of experiments performed in duplicate. The significance of differences was determined by the paired or unpaired Student t test. Unless otherwise stated, data are not significantly different from control values.
| |
RESULTS |
|---|
|
|
|---|
Opsonic and nonopsonic phagocytosis of zymosan and mycobacteria by
CR3-transfected and WT CHO cells.
To study whether zymosan and
mycobacteria interacted with distinct lectin sites on CR3,
CR3-transfected CHO cells were used to avoid interaction with other
macrophage receptors. As previously observed (8, 14),
expression of CR3 on transfected CHO cells was homogenous, since a
single cell population was detected by immunofluorescence flow
cytometry (Fig. 1A).
|
Differential inhibitory effects of polysaccharides on phagocytosis of zymosan and M. kansasii by CR3-transfected CHO cells. The above-mentioned results showed that zymosan and pathogenic mycobacteria can both be ingested nonopsonically by CR3. Because CR3 can also bind to a variety of polysaccharides, we then investigated whether distinct sugars could compete for zymosan or M. kansasii recognition.
At the concentrations used, all the polysaccharides tested except NADG inhibited, but to a low degree, phagocytosis of zymosan and M. kansasii (Fig. 2). No further inhibition was obtained when larger amounts of sugar were used (not shown). Even
-glucan, which accounts for 70% of the polysaccharides
in the capsule of M. kansasii (30), only
partially inhibited the ingestion of mycobacteria. With a combination
of
-glucan and mannan, the inhibitory effects of individual sugars
were additive on zymosan phagocytosis but, surprisingly, not on
M. kansasii phagocytosis. Although difficult to interpret,
this result suggests that zymosan and M. kansasii may not
use the same lectin site of CR3. However, given the small inhibitory
effects of individual sugars, another approach was required to support
this hypothesis.
|
Differential inhibitory effects of anti-CR3 MAbs on zymosan and
M. kansasii phagocytosis by CR3-transfected CHO cells.
For this purpose, we used a panel of well-characterized MAbs directed
against different epitopes of the CD11b extracellular domain of CR3. A
schematic representation of the regions recognized by these different
MAbs is shown in Fig. 3A.
|
|
Differential induction of NADPH oxidase activity by zymosan and
M. kansasii following their phagocytosis via CR3 in
differentiated U937 cells.
It has been shown that nonopsonic
phagocytosis of zymosan by macrophages elicited
O2
production (2, 10, 24) whereas
that of M. kansasii did not (2). We thus wondered
whether such different effects could be related to the above-mentioned
results showing distinct types of phagocytosis of these two particles
by CR3. This was investigated using U937 cells, because upon
differentiation into macrophages, these cells express CR3 and the
O2
-generating enzyme NADPH oxidase but do not
express the mannose receptor (Table 1),
which is also involved in the nonopsonic phagocytosis of zymosan and
mycobacteria (2, 45, 50).
|
|
(superoxide anions) or immunofluorescence microscopy to detect p47phox
translocation to phagosomes. p47phox is a cytosolic component of NADPH
oxidase which translocates to membranes to participate in the
functional assembly of the enzyme (13). Zymosan was able to
significantly activate the production of O2
and the translocation of p47phox, whereas M. kansasii was
not (Fig. 5C and 6). Several controls
were performed to ensure that the absence of
O2
production did not result from an active
effect of mycobacteria (Table 2).
Production of O2
was not modified when viable
M. kansasii were coincubated with stimulating agents, such
as phorbol myristate acetate (PMA), opsonized zymosan, or zymosan,
excluding a free-radical-scavenging effect of these bacteria or a
direct inhibitory effect on the enzyme per se. Furthermore, heat-killed
M. kansasii gave results similar to those with live
mycobacteria. Finally, when IgG and complement-opsonized mycobacteria
were internalized through receptors known to trigger O2
generation, the
O2
production was indeed stimulated further,
indicating that M. kansasii was unable to inhibit NADPH
oxidase.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
In the present study we showed that distinct regions of CR3 are
involved in the nonopsonic phagocytosis of mycobacteria and zymosan and
transduce different intracellular signals, since zymosan phagocytosis
triggers production of O2
whereas M. kansasii phagocytosis does not.
Only pathogenic mycobacterial species such as M. kansasii and M. avium were efficiently internalized under nonopsonic conditions by CR3-transfected CHO cells, whereas the nonpathogenic species M. smegmatis and M. phlei were not. Under similar conditions, M. tuberculosis, but not M. smegmatis, efficiently binds to CR3 in CHO-transfected cells (8). This discriminative property of CR3 also occurred in U937 cells, where upregulation of CR3 induced by differentiation correlated with a parallel increase in phagocytosis of M. kansasii (Table 2 and Fig. 5A) but not M. phlei (unpublished results). This suggests that CR3 may constitute a safe portal of entry for pathogenic mycobacteria, underlying its role in mycobacterial-mediated infectious diseases.
The double specificity of CR3 for mannose- and glucose-containing
polysaccharides (55) has suggested that CR3 has either two
lectin sites or a unique site with degenerated specificity (55,
65). To determine whether zymosan and M. kansasii are recognized by CR3 through distinct sugars, competition experiments were
performed with single mono- or polysaccharides. The clear inhibition of
zymosan ingestion obtained by combining
-glucan and mannan suggested
that internalization of this particle might involve two subsites of CR3
specific for glucose and mannose moieties, respectively. In contrast,
this sugar combination did not produce a significant inhibitory effect
on M. kansasii phagocytosis, in line with the previous
observation that laminarin (a polymer of
-glucan) and mannan
minimally inhibited the adherence of nonopsonized M. tuberculosis to CR3-transfected CHO cells (Schlesinger et al.). It
is possible that ingestion of mycobacteria by CR3 either involves different molecules or more complex saccharides than ingestion of
zymosan or is highly sensitive to the sugar environment on the
bacteria. Indeed, antigen 85C, present on the surfaces of mycobacteria,
has been shown to promote the binding of microbeads coated with
mycobacterial products to CR3 (20). In the same way, the
affinity of the mannose receptor is significantly increased when
mannose moieties are contained in complex mycobacterial glycoconjugates (48, 54). Also, lectins, such as type 1-fimbriae from
Escherichia coli, could bind to glycosylated proteins at the
surfaces of host cells (18), but none has been specifically
described in pathogenic mycobacteria. In any case, the different
inhibitory actions of sugars on nonopsonic phagocytosis of zymosan and
M. kansasii by CR3 suggested that the respective underlying
mechanisms are quite different.
The differential blocking effects of a panel of MAbs on the CD11b
extracellular domain further support the above conclusion. Indeed,
LM2/1 and OKM1 MAbs, which have both been reported to block the lectin
site of CR3 (8, 14, 55), inhibited ingestion of zymosan but
not M. kansasii. This shows that the
-glucan site of CR3
is probably not involved in M. kansasii ingestion but
confirms its major role in the recognition of zymosan. Furthermore,
almost all of the other MAbs used, with their cognate epitopes
scattered throughout the extracellular domain of CD11b (Fig. 3A), were
able to individually block zymosan ingestion. Only combinations of pairs of three of these, which recognized epitopes restricted to the
N-terminal part of CD11b, efficiently blocked M. kansasii phagocytosis.
The patterns of antibody inhibition of M. tuberculosis (8) and M. kansasii (this study) differ to some extent. This could be explained by differences between the strains used, because even in a single strain, differences have been reported: of two substrains of H37Rv, one binds to CR3 and the other does not (9), and, depending on the physiological state of M. avium, it can or cannot be ingested through CR3 (5).
We also report that an antibody, 2LPM, directed against the recognition
site of iC3b can efficiently inhibit the nonopsonic phagocytosis of
both zymosan and M. kansasii. It is noteworthy, however,
that binding of iC3b impairs subsequent binding of nonopsonized yeast
and
-glucan particles (41), and 2LPM MAbs have been shown to reduce nonopsonic binding of M. tuberculosis to CR3
(8). These observations suggest that once the iC3b binding
site is occupied either by its natural ligand or by antibodies, this
affects the functionality of or sterically blocks the
-glucan
binding site, as previously proposed (40, 55). Whatever the
mode of action of the antibodies used (i.e., steric hindrance or
conformational modifications), their differential effects on the
phagocytosis of zymosan versus that of M. kansasii again
highlights the fact that these two types of particles do not interact
in similar ways with CR3 under nonopsonic conditions.
Although we do not exclude the possibility that other receptors could contribute to nonopsonic phagocytosis, in differentiated U937 cells which do not express the mannose receptor, ingestion of zymosan and M. kansasii largely occurred through CR3. Indeed, phagocytosis correlated with the increase in CR3 expression and was inhibited by the MAb 2LPM. As in other phagocytes, CR3 expressed in U937 cells may interact with accessory molecules, such as CD87 or CD14 (see reference 43 for a review). In these cells, it has been demonstrated (43) that such interactions may generate conformational changes of the I domain recognized by 2LPM MAbs. Such accessory receptors may be different in CHO cells, explaining the smaller inhibitory effect of 2LPM MAbs on M. kansasii phagocytosis compared to that observed in U937 cells.
Finally, using U937 cells, we also showed that CR3-mediated
phagocytosis of zymosan induced O2
production, whereas ingestion of M. kansasii did not. The
observation that CR3 can initiate distinct cell responses depending on
the binding site recognized by particles correlates with previous data
obtained with neutrophils. In these cells, which also express CR3 but
not the mannose receptor, unopsonized zymosan stimulates O2
production whereas it fails to do so when
particles are iC3b coated (60, 64). We demonstrated that
M. kansasii and zymosan use the same receptor, but their
coincubation (Table 2) did not affect the production of
O2
triggered by zymosan, probably because the
number of receptors at the cell surface is not limiting. The fact that
phagocytosis of M. kansasii did not modify
O2
production induced by different
stimulating agents demonstrates that the bacteria did not directly
inhibit NADPH oxidase activity per se or scavenged
O2
. These data suggest that phagocytosis via
CR3 may occur through several cellular pathways, the one leading to
nonopsonic internalization of M. kansasii being either not
coupled to NADPH oxidase activation or specifically inhibited by a
bacterial component(s) before O2
production is initiated. In this respect, it is noteworthy
that the mannose receptor, which is thought to be an important receptor for nonopsonic phagocytosis of mycobacteria, also appears not to be
coupled to bactericidal responses (2).
Although phagocytosis is more effective in the presence of serum
(21, 45, 46), nonopsonic internalization of mycobacteria by
phagocytes has clearly been demonstrated (2, 8, 21, 34, 45, 46,
52). The question of nonopsonic versus opsonic binding of
mycobacteria to phagocytes is important, because seric opsonins may be
limiting in the alveolar space where the tuberculosis primary infection
takes place (8, 39). We showed here that CR3, which is
expressed in lung alveolar macrophages, selectively internalized
pathogenic mycobacteria under nonopsonic conditions, and this did not
elicit production of O2
. We therefore suggest
that CR3 might constitute a safe portal of entry for mycobacteria. In
addition to CR3, mycobacteria have been shown to enter nonopsonically
into macrophages through several receptors (2, 25, 36, 37,
66), but their relative participation in in vivo infections is
difficult to establish. In CD18-deficient mice, a comparable level of
tissue infection by M. avium has been reported, suggesting
to us that when a phagocytic receptor is lacking, mycobacteria use
another one (4). It is therefore difficult to conclude from
these experiments whether CR3 is involved in primary mycobacterial
infection in human lungs. To determine the receptor hierarchy in
nonopsonic phagocytosis of mycobacteria, experiments on both human
macrophages and cells transfected with one or combinations of
phagocytic receptors should be performed. This would shed light on
invasion strategies of pathogens and help to determine whether the mode
of binding and the route of entry play roles in the subsequent
bactericidal responses and the fate of mycobacteria.
| |
ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the Ministère de l'Education Nationale de la Recherche et de la Technologie, Programme de Microbiologie, from Sidaction, from E. C. grant no. QLK2CT 1999-01093 TB vaccine cluster, and from the Région Midi-Pyrénées (grant no. 97002346).
We gratefully acknowledge T. A. Springer, M. R. W. Ehlers, and W. B. Nauseef for the generous gifts of anti-CD11b
MAbs, CR3-transfected CHO cells, and anti-p47phox antibodies. We thank
M. Daffé for
-glucan and, together with L. Emorine and C. Astarie-Dequecker, for discussion and critical evaluation of the manuscript.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: IPBS, CNRS UMR5089, 205 Route de Narbonne, 31077 Toulouse Cedex, France. Phone: 33-561 17 54 58. Fax: 33-561 17 59 94. E-mail: maridono{at}ipbs.fr.
Editor: S. H. E. Kaufmann
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Armstrong, J. A., and P. D. Hart.
1975.
Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli.
J. Exp. Med.
142:1-16 |
| 2. |
Astarie-Dequeker, C.,
E. N. N'Diaye,
V. Le Cabec,
M. G. Rittig,
J. Prandy, and I. Maridonneau-Parini.
1999.
The mannose receptor mediates uptake of pathogenic and nonpathogenic mycobacteria and bypasses bactericidal responses in human macrophages.
Infect. Immun.
67:469-477 |
| 3. |
Balsam, L. B.,
T. W. Liang, and C. A. Parkos.
1998.
Functional mapping of CD11b/CD18 epitopes important in neutrophil-epithelial interactions: a central role of the I domain.
J. Immunol.
160:5058-5065 |
| 4. |
Bermudez, L. E.,
J. Goodman, and M. Petrofsky.
1999.
Role of complement receptors in uptake of Mycobacterium avium by macrophages in vivo: evidence from studies using CD18-deficient mice.
Infect. Immun.
67:4912-4916 |
| 5. | Bermudez, L. E., A. Parker, and J. R. Goodman. 1997. Growth within macrophages increases the efficiency of Mycobacterium avium in invading other macrophages by a complement receptor-independent pathway. Infect. Immun. 65:1916-1925[Abstract]. |
| 6. |
Bermudez, L. E.,
L. S. Young, and H. Enkel.
1991.
Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins.
Infect. Immun.
59:1697-1702 |
| 7. | Cooper, A., H. Rosen, and J. M. Blackwell. 1988. Monoclonal antibodies that recognize distinct epitopes of the macrophage type three complement receptor differ in their ability to inhibit binding of Leishmania promastigotes harvested at different phases of their growth cycle. Immunology 65:511-514[Medline]. |
| 8. | Cywes, C., N. L. Godenir, H. C. Hoppe, R. R. Scholle, L. M. Steyn, R. E. Kirsch, and M. R. W. Ehlers. 1996. Nonopsonic binding of Mycobacterium tuberculosis to human complement receptor type 3 expressed in Chinese hamster ovary cells. Infect. Immun. 64:5373-5383[Abstract]. |
| 9. | Cywes, C., H. C. Hoppe, M. Daffé, and M. R. W. Ehlers. 1997. Nonopsonic binding of Mycobacterium tuberculosis to complement receptor type 3 is mediated by capsular polysaccharides and is strain dependent. Infect. Immun. 65:4258-4266[Abstract]. |
| 10. |
Czop, J. K., and K. F. Austen.
1985.
A -glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway.
J. Immunol.
134:2588-2593[Abstract].
|
| 11. | Daffé, M., and P. Draper. 1998. The envelope layers of mycobacteria with reference to their pathogenicity. Adv. Microbiol. Physiol. 39:131-203[Medline]. |
| 12. | Dana, N., B. Styrt, J. D. Griffin, R. F. Todd, M. S. Klemper, and M. A. Arnaout. 1986. Two functional domains in the phagocyte membrane glycoprotein Mo1 identified with monoclonal antibodies. J. Immunol. 137:3259-3263[Abstract]. |
| 13. |
DeLeo, F. R.,
L. A. H. Allen,
M. Apicella, and W. M. Nauseef.
1999.
NADPH oxidase activation and assembly during phagocytosis.
J. Immunol.
163:6732-6740 |
| 14. |
Diamond, M. S.,
J. Garcia-Aguilar,
J. K. Bickfotd,
A. L. Corbi, and T. A. Springer.
1993.
The I-domain is a major recognition site on the leukocyte integrin Mac-1 (CD11b/CD18) for four distinct adhesion ligands.
J. Cell Biol.
120:1031-1043 |
| 15. | Di Carlo, F. J., and J. V. Fiore. 1957. On the composition of zymosan. Science 127:756-757. |
| 16. |
Drevets, D. A., and P. A. Campbell.
1991.
Roles of complement and complement receptor type 3 in phagocytosis of Listeria monocytogenes by inflammatory mouse peritoneal macrophages.
Infect. Immun.
59:2645-2652 |
| 17. | Gahmberg, C. G. 1997. Leukocyte adhesion: CD11/CD18 integrins and intercellular adhesion molecules. Curr. Opin. Cell Biol. 9:643-650[CrossRef][Medline]. |
| 18. |
Gbarah, A.,
C. G. Gahmberg,
I. Ofek,
U. Jacobi, and N. Sharon.
1991.
Identification of the leukocyte adhesion molecules CD11 and CD18 as receptors for type 1-fimbriated (mannose-specific) Escherichia coli.
Infect. Immun.
59:4524-4530 |
| 19. | Graham, I. L., and E. J. Brown. 1991. Extracellular calcium results in a conformational change in Mac1 (CD11b/CD18) on neutrophils. Differentiation of adhesion and phagocytosis functions of Mac1. J. Immunol. 146:685-691[Abstract]. |
| 20. | Hetland, G., and H. G. Wiker. 1994. Antigen 85C on Mycobacterium bovis, BCG and M. tuberculosis promotes monocyte-CR3-mediated uptake of microbeads coated with mycobacterial products. Immunology 82:445-449[Medline]. |
| 21. |
Hirsch, C. S.,
J. J. Ellner,
D. G. Russell, and E. A. Rich.
1994.
Complement receptor-mediated uptake and tumor necrosis factor- -mediated growth inhibition of Mycobacterium tuberculosis by human alveolar macrophages.
J. Immunol.
152:743-753[Abstract].
|
| 22. |
Hondalus, M. K.,
M. S. Diamond,
L. A. Rosenthal,
T. A. Springer, and D. M. Mosser.
1993.
The intracellular bacterium Rhodococcus equi requires Mac-1 to bind to mammalian cells.
Infect. Immun.
61:2919-2929 |
| 23. |
Joiner, K. A.,
S. A. Fuhrman,
H. M. Miettinen,
L. H. Kasper, and I. Mellman.
1990.
Toxoplasma gondii: fusion competence of parasitophorous vacuole in Fc receptor-transfected fibroblasts.
Science
249:641-646 |
| 24. |
Kadish, J. L.,
C. C. Choi, and J. K. Czop.
1986.
Phagocytosis of unopsonized zymosan particles by trypsin-sensitive and -glucan-inhibitable receptors on bone marrow-derived murine macrophages.
Immunol. Res.
5:129-138[Medline].
|
| 25. | Khanna, K. V., C. S. Choi, G. Gekker, P. K. Peterson, and T. W. Molitor. 1996. Differential infection of porcine alveolar macrophage subpopulations by nonopsonized Mycobacterium bovis involves CD14 receptors. J. Leukoc. Biol. 60:214-220[Abstract]. |
| 26. |
Kuhn, S. E.,
A. Nardin,
P. E. Klebba, and R. P. Taylor.
1998.
Escherichia coli bound to the primate erythrocyte complement receptor via bispecific monoclonal antibodies are transferred to and phagocytosed by human monocytes in an in vitro model.
J. Immunol.
160:5088-5097 |
| 27. |
Le Cabec, V.,
J. Calafat, and N. Borregaard.
1997.
Sorting of the specific granule protein, NGAL, during granulocytic maturation of HL-60 cells.
Blood
89:2113-2121 |
| 28. | Le Cabec, V., and I. Maridonneau-Parini. 1994. Annexin 3 is associated with cytoplasmic granules in neutrophils and monocytes and translocates to the plasma membrane in activated cells. Biochem. J. 303:481-487. |
| 29. |
Le Cabec, V., and I. Maridonneau-Parini.
1995.
Complete and reversible inhibition of NADPH oxidase in human neutrophils by phenylarsine oxide at a step distal to membrane translocation of the enzyme subunits.
J. Biol. Chem.
270:2067-2073 |
| 30. |
Lemassu, A.,
A. Ortalo-Magne,
F. Bardou,
G. Silve,
M. A. Lanéelle, and M. Daffé.
1996.
Extracellular and surface-exposed polysaccharides of non-tuberculous mycobacteria.
Microbiology
142:1513-1520 |
| 31. |
Lu, C.,
C. Oxvig, and T. A. Springer.
1998.
The structure of the -propeller domain and C-terminal region of the integrin M subunit. Dependence on subunit association and prediction of domains.
J. Biol. Chem.
273:15138-15147 |
| 32. | Maridonneau-Parini, I., C. Z. Yang, M. Bornens, and B. Goud. 1991. Increase in the expression of a family of small guanosine triphosphate-binding proteins, rab proteins, during induced phagocyte differentiation. J. Clin. Investig. 87:901-907. |
| 33. | Nakajima, H., M. Kizaki, H. Ueno, A. Muto, N. Takayama, H. Matsushita, A. Sonoda, and Y. Ikeda. 1996. All-trans and 9-cis retinoic acid enhance 1,25-dihydroxyvitamin D3-induced monocytic differentiation of U937 cells. Leukemia Res. 20:665-676[CrossRef][Medline]. |
| 34. |
N'Diaye, E. N.,
X. Darzacq,
C. Astarie-Dequeker,
M. Daffé,
J. Calafat, and I. Maridonneau-Parini.
1998.
Fusion of azurophil granules with phagosomes and activation of the tyrosine kinase Hck are specifically inhibited during phagocytosis of mycobacteria by human neutrophils.
J. Immunol.
161:4983-4991 |
| 35. |
Payne, N. R., and M. A. Horwitz.
1987.
Phagocytosis of Legionella pneumophila is mediated by human monocyte complement receptors.
J. Exp. Med.
166:1377-1389 |
| 36. | Peterson, P. K., G. Gekker, S. Hu, W. S. Sheng, W. R. Anderson, R. J. Ulevitch, P. S. Tobias, K. V. Gustafson, T. W. Molitor, and C. C. Chao. 1995. CD14 receptor-mediated uptake of nonopsonized Mycobacterium tuberculosis by human microglia. Infect. Immun. 63:1598-1602[Abstract]. |
| 37. |
Rao, S. P.,
K. Ogata, and A. Catanzaro.
1993.
Mycobacterium avium-M. intracellulare binds to the integrin receptor v 3 on human monocyte-derived macrophages.
Infect. Immun.
61:663-670 |
| 38. | Relman, D., E. Tuomanen, S. Falkow, D. T. Golenbock, K. Saukkonen, and S. D. Wright. 1990. Recognition of a bacterial adhesin by an integrin: macrophage CR3 (CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 61:1375-1382[CrossRef][Medline]. |
| 39. | Reynolds, H. Y., and H. N. Newball. 1974. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J. Lab. Clin. Med. 84:559-573[Medline]. |
| 40. | Ross, G. D., J. A. Cain, and P. J. Lachmann. 1985. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J. Immunol. 134:3307-3314[Abstract]. |
| 41. |
Ross, G. D.,
J. A. Cain,
B. L. Myones,
S. L. Newman, and P. J. Lachman.
1987.
Specificity of membrane complement receptor type three (CR3) for -glucans.
Complement
4:61-74[Medline].
|
| 42. | Ross, G. D., and V. Vetvicka. 1993. CR3 (CD11b, CD18): a phagocyte and NK cell membrane receptor with multiple ligand specificities and functions. Clin. Exp. Immunol. 92:181-184[Medline]. |
| 43. |
Ross, G. D.,
V. Vetvicka,
J. Yan,
Y. Xia, and J. Vetvickova.
1999.
Therapeutic intervention with complement and -glucan in cancer.
Immunopharmacology
42:61-74[CrossRef][Medline].
|
| 44. |
Russell, D. G., and S. D. Wright.
1988.
Complement receptor type 3 (CR3) binds to an Arg-Gly-Asp-containing region of the major surface glycoprotein, gp63, of Leishmania promastigotes.
J. Exp. Med.
168:279-292 |
| 45. | Schlesinger, L. S. 1993. Macrophage phagocytosis of virulent but not attenuated strains of Mycobacterium tuberculosis is mediated by mannose receptors in addition to complement receptors. J. Immunol. 150:2920-2930[Abstract]. |
| 46. | Schlesinger, L. S., C. G. Bellinger-Kawahara, N. R. Payne, and M. A. Horwitz. 1990. Phagocytosis of Mycobacterium tuberculosis is mediated by human monocyte complement receptors and complement component C3. J. Immunol. 144:2771-2780[Abstract]. |
| 47. | Schlesinger, L. S., and M. A. Horwitz. 1990. Phagocytosis of leprosy bacilli is mediated by complement receptors CR1 and CR3 on human monocytes and complement component C3 in serum. J. Clin. Investig. 85:1304-1314. |
| 48. | Schlesinger, L. S., S. R. Hull, and T. M. Kaufman. 1994. Binding of the terminal mannosyl units of lipoarabinomannan from a virulent strain of Mycobacterium tuberculosis to human macrophages. J. Immunol. 152:4070-4079[Abstract]. |
| 49. | Sengelov, H. 1995. Complement receptors in neutrophils. Crit. Rev. Immunol. 15:107-131[Medline]. |
| 50. | Speert, D. P., and S. C. Silverstein. 1985. Phagocytosis of unopsonized zymosan by human monocyte-derived macrophages: maturation and inhibition by mannan. J. Leukoc. Biol. 38:655-658[Abstract]. |
| 51. |
Steadman, R.,
M. M. Petersen,
N. Topley,
D. Williams,
N. Matthews,
B. Spur, and J. D. Williams.
1990.
Differential augmentation by recombinant human tumor necrosis factor- of neutrophil responses to particulate zymosan and glucan.
J. Immunol.
144:2712-2718[Abstract].
|
| 52. | Stokes, R. W., I. D. Haidl, W. A. Jefferies, and D. P. Speert. 1993. Mycobacteria-macrophage interactions: macrophage phenotype determines the nonopsonic binding of Mycobacterium tuberculosis to murine macrophages. J. Immunol. 151:7067-7076[Abstract]. |
| 53. |
Stokes, R. W.,
L. M. Thorson, and D. P. Speert.
1998.
Nonopsonic and opsonic association of Mycobacterium tuberculosis with resident alveolar macrophages is inefficient.
J. Immunol.
160:5514-5521 |
| 54. |
Taylor, M. E., and K. Drickamer.
1993.
Structural requirements for high affinity binding of complex ligands by the macrophage mannose receptor.
J. Biol. Chem.
268:399-404 |
| 55. |
Thornton, B. P.,
V. Vetvicka,
M. Pitman,
R. C. Goldman, and G. D. Ross.
1996.
Analysis of the sugar specificity and molecular location of the -glucan-binding lectin site of complement receptor type 3 (CD11b/CD18).
J. Immunol.
156:1235-1246[Abstract].
|
| 56. |
Ugarova, T. P.,
D. A. Solovjov,
L. Zhang,
D. I. Loukinov,
V. C. Yee,
L. V. Medved, and E. F. Plow.
1998.
Identification of a novel recognition sequence for integrin M 2 within the -chain of fibrinogen.
J. Biol. Chem.
273:22519-22527 |
| 57. | Valentin-Weigand, P., P. Benkel, M. Rohde, and G. S. Chhatwal. 1996. Entry and intracellular survival of group B streptococci in J774 macrophages. Infect. Immun. 64:2467-2473[Abstract]. |
| 58. |
Van Strijp, J. A. G.,
D. G. Russel,
E. Tuomanen,
E. J. Brown, and S. D. Wright.
1993.
Ligand specificity of purified complement receptor type three (CD11b/CD18, M 2, Mac1).
J. Immunol.
151:3324-3336[Abstract].
|
| 59. |
Vetvicka, V.,
B. P. Thornton, and G. D. Ross.
1996.
Soluble -glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells.
J. Clin. Investig.
98:50-61[Medline].
|
| 60. | Williams, J. D., N. Topley, H. M. Alobaidi, and M. J. Harber. 1986. Activation of human polymorphonuclear leukocytes by particulate zymosan is related to both its major carbohydrate components: glucan and mannan. Immunology 58:117-124[Medline]. |
| 61. |
Wilson, S. D., and R. D. Pearson.
1988.
Roles of CR3 and mannose receptors in the attachment and ingestion of Leishmania donovani by human mononuclear phagocytes.
Infect. Immun.
56:363-369 |
| 62. |
Wright, S. D., and T. C. Jong.
1986.
Adhesion-promoting receptors on human macrophages recognize Escherichia coli by binding to lipopolysaccharide.
J. Exp. Med.
164:1876 |
| 63. |
Wright, S. D.,
S. M. Levin,
M. T. C. Jong,
Z. Chad, and L. G. Kabbash.
1989.
CR3 (CD11b/CD18) expresses one binding site for Arg-Gly-Asp-containing peptides and a second site for bacterial lipopolysaccharide.
J. Exp. Med.
169:175-183 |
| 64. |
Wright, S. D., and S. C. Silverstein.
1983.
Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes.
J. Exp. Med.
158:2016-2023 |
| 65. |
Yu, X.,
V. Vetvicka,
J. Yan,
M. Hanikyrova,
T. Mayadas, and G. D. Ross.
1999.
The -glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.
J. Immunol.
162:2281-2290 |
| 66. | Zimmerli, S., S. Edwards, and J. Ernst. 1996. Selective receptor blockage during phagocytosis does not alter the survival and growth of Mycobacterium tuberculosis in human macrophages. Am. J. Respir. Cell. Mol. Biol. 15:760-770[Abstract]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»